FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Denies Attorneys Simufilam Petition

FDA denies as inappropriate a citizen petition asking it to halt two Cassava Sciences simufilam trials and investigate concerns about the trials.

Human Drugs

Priority Review for Dupixent sBLA

FDA approves for priority review a Sanofi sBLA for Dupixent to treat moderate-to-severe atopic dermatitis in children 6 months to 5 years old.

Human Drugs

Feds Have Tools to Cut Drug Prices: Report

Researchers from Harvard Medical School and the Engelberg Foundation call on the U.S. government to exercise its legal rights to obtain drugs develope...

Human Drugs

FDA Fast Track for Bayer Blood Thinner

FDA grants Bayer a fast track designation for its investigational blood thinner asundexian (BAY2433334) its use as secondary prevention in patients wi...

Human Drugs

Public Citizen Wants Gabapentin Scheduled

Public Citizen asks FDA and the Drug Enforcement Administration to add gabapentin products to Schedule V of the Controlled Substances Act.

Human Drugs

Panel Votes Down Single-Country Clinical Trial

An FDA advisory committee votes 14 to 1 that Innovent Biologics and Eli Lillys China-developed me too checkpoint inhibitor sintilimab plus chemotherap...

Human Drugs

Compounding Center Sales Head Sentenced

A Massachusetts federal judge sentences the former national sales director for the defunct New England Compounding Center to time served for defraudin...

FDA General

Califf Nomination Stalled: Report

An Associated Press report says the nomination of Robert Califf to be FDA commissioner is in doubt due to opposition from both Democrats and Republica...

Human Drugs

Sanofis Enjaymo OKd for Cold Agglutinin Disease

FDA approves a Sanofi BLA for Enjaymo (sutimlimab-jome) for decreasing the need for red blood cell transfusions due to hemolysis in adults with cold a...

Federal Register

Info Collection on Generic User Fee Program Revised

Federal Register notice: FDA sends to OMB an information collection revision entitled Generic Drug User Fee Program.